Cargando…

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

The clinical benefit of MAPK pathway inhibition in BRAF-mutant melanoma patients is limited by the development of acquired resistance. Using drug-naïve cell lines derived from tumor specimens, we established a preclinical model of melanoma resistance to vemurafenib or trametinib to provide insight i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartman, Mariusz L., Sztiller-Sikorska, Malgorzata, Gajos-Michniewicz, Anna, Czyz, Malgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017165/ https://www.ncbi.nlm.nih.gov/pubmed/31936151 http://dx.doi.org/10.3390/cells9010142

Ejemplares similares

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)

17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of (V600E)BRAF melanoma cells and their response to vemurafenib and trametinib in vitro
por: Zalesna, Izabela, et al.
Publicado: (2017)

Natural Compounds' Activity against Cancer Stem-Like or Fast-Cycling Melanoma Cells
por: Sztiller-Sikorska, Malgorzata, et al.
Publicado: (2014)

MCL-1, BCL-X(L) and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
por: Hartman, Mariusz L., et al.
Publicado: (2015)

WNT Signaling in Melanoma
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2020)

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations
por: Hartman, Mariusz L., et al.
Publicado: (2016)

Gene Expression Profiling Identifies Microphthalmia-Associated Transcription Factor (MITF) and Dickkopf-1 (DKK1) as Regulators of Microenvironment-Driven Alterations in Melanoma Phenotype
por: Hartman, Mariusz L., et al.
Publicado: (2014)

Role of miRNAs in Melanoma Metastasis
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2019)

Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres
por: Czyz, Malgorzata, et al.
Publicado: (2013)

Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
por: Sztiller-Sikorska, Malgorzata, et al.
Publicado: (2020)

WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2023)

Melanoma-Derived Extracellular Vesicles Bear the Potential for the Induction of Antigen-Specific Tolerance
por: Düchler, Markus, et al.
Publicado: (2019)

Pentoxifylline Inhibits WNT Signalling in β-Catenin(high) Patient-Derived Melanoma Cell Populations
por: Talar, Beata, et al.
Publicado: (2016)

TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
por: Hartman, Mariusz L., et al.
Publicado: (2019)

Physiologically Relevant Oxygen Concentration (6% O(2)) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
por: Osrodek, Marta, et al.
Publicado: (2019)

Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal
por: Hartman, Mariusz L., et al.
Publicado: (2023)

MITF in melanoma: mechanisms behind its expression and activity
por: Hartman, Mariusz L., et al.
Publicado: (2014)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
por: Koziej, Paulina, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond †
por: Bojarska, Joanna, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
por: Audrito, Valentina, et al.
Publicado: (2020)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lr64n6h69pp6scmmurijfc4p3j